Semax was built to last. The experiment is less tidy.
A short ACTH fragment, an added tail and a rat study that still finds rapid breakdown: the engineering history is more interesting than a blanket claim about focus.
Semax peptide construction
Semax is a synthetic seven-amino-acid peptide, Met-Glu-His-Phe-Pro-Gly-Pro. Its first four residues come from ACTH, the pituitary hormone involved in cortisol release; this fragment lacks that cortisol-releasing activity. The Pro-Gly-Pro tail was added to slow enzymatic breakdown.
I like the modesty of the original engineering problem. There was a short-lived fragment with interesting biological activity, and an attempt to give it a longer window. That is a concrete meaning of new, rather than a claim that the whole brain can be upgraded.
The radiolabeled Semax experiment in rats complicates the neat version. Within two minutes of intranasal administration, about 0.093% of the administered radioactivity per gram appeared in brain; about 80% of that early signal was intact Semax. Rapid breakdown followed. Those measurements describe rats; the duration of an effect in people remains a separate question.
Neurotrophin gene expression in rats
The Semax mechanism is often compressed into a growth-factor slogan. BDNF and NGF are neurotrophins, proteins involved in the maintenance and growth of neurons. The rat neurotrophin gene-expression study found increases in hippocampal NGF and BDNF, and increases in BDNF in other regions, but NGF fell in frontal cortex. Region and gene mattered.
Another rat basal-forebrain study of binding and BDNF protein found a rapid BDNF protein increase there, but not in cerebellum, along with a specific, reversible, calcium-dependent binding site. Gene expression and protein measurement are related observations; they are not interchangeable.
The shorthand led me to expect everything to rise. The regional decrease makes the biology more interesting and the shorthand less useful. A response that differs across brain regions is harder to turn into a universal claim about better memory.
Semax in injury models
In rats with experimentally induced cortical ischemia, Semax reduced infarct volume and improved retention of a passive-avoidance response, a memory task. A separate genome-wide study of rat focal ischemia found that more than 50% of the affected genes were immune-related, with vascular changes also prominent. This broad response to injury extends beyond a single growth factor moving upward.
The 2025 spinal-cord-injury study in female mice adds another route into that problem: improved locomotor recovery and reduced pyroptosis, an inflammatory form of cell death, through an Oprm1/USP18/FTO pathway. The mice had spinal-cord injuries. They were not healthy people trying to concentrate.
The injured population decides how much weight I give that newer paper. A new animal experiment can deepen the injury story while leaving the everyday enhancement claim almost where it was.
In-vitro human-serum enzyme assay
The enzyme experiment using human serum found that Semax and Selank inhibited enzymes that break down enkephalins, the body’s own opioid peptides. It was an in-vitro assay, meaning the work happened outside a living person. It did not measure pain relief, mood or focus in patients.
That distinction also limits the interaction story. Enzyme inhibition and the broad gene-expression effects give reasons to investigate combinations with other medicines, but the available work does not establish their safety. Long-term safety in healthy people, pregnancy and breastfeeding remains uncharacterized.
Semax has prescription-drug registration in Russia and Ukraine; it has no FDA- or EMA-approved indication. In the United States, clinical prescribing requires an individual assessment, and research-labelled material remains a separate supply channel. The existing clinical literature is geographically concentrated, with no published Western randomized controlled trials. Registration in one setting does not fill the missing evidence in another.
Anecdotal reports about Semax
Community accounts describe clearer thinking, sustained focus, easier word recall and mood changes. Other accounts describe very little, or nothing noticeable. Nasal irritation, headache, fatigue, irritability and disrupted sleep also appear. These are anecdotal accounts, not clinical evidence, and the reports do not establish how often any effect occurs.
I’m reluctant to translate clarity into a molecular explanation. A person’s description can be sincere without identifying BDNF, an active metabolite or any other cause. The rat clearance measurements do not prove why a forum account faded.
For Semax, the next persuasive change would be a well-controlled human study that names its population, measures the claimed benefit and follows safety. Until then, its engineered tail and its injury-model biology are the substantive story. Selank’s different ancestry makes a useful companion to it.